Premature Ovarian Insufficiency: Hormone Replacement Therapy and Follow-Up

This chapter describes causes, diagnostic and therapeutic procedures in the event of premature ovarian insufficiency (POI) induced either by gonadotoxic treatments or caused by genetic defects, autoimmunological disease, infection, surgical interventions, etc. POI is defined by oligo-/amenorrhea for at least 4 months and a serum concentration of FSH > 25 IU/I measured twice at least 4 weeks apart in women before the age of 40 years. Women with POI generally show the typical symptoms of menopause such as cycle disorders, hot flushes, vaginal dryness, sleep disorders and psychological changes such as nervousness, irritability, fatigue and others. Fertility of POI patients is severely reduced and total infertility can occur. The lack of estrogen leads to considerable long-term consequences. These are primarily effects on bone metabolism, the cardiovascular system and changes in the nervous system that result in a reduced life expectancy. The misinterpretation of the WHI (Women’s Health Initiative) study has led to an irrational fear of hormone replacement therapy (HRT) for both patients and doctors. However, with the increased risk associated with POI/early menopause HRT is advantageous if the oncological and other contraindications to HRT are followed. The risks of non-HRT must therefore be weighed individually against the risks of HRT. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others

Hamoda H, British Menopause Society and Women’s Health Concern. The British Menopause Society and Women's Health Concern recommendations on the management of women with premature ovarian insufficiency. Post Reprod Health. 2017;23:22–35. Coccia ME, Rizzello F, Mariani G, Bulletti C, Palagiano A, Scarselli G. Ovarian surgery for bilateral endometriomas influences age at menopause. Hum Reprod. 2011;26:3000–7. Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol. 2002;29:2571–6. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13:673–8. Oktem O, Kim SS, Selek U, Schatmann G, Urman B. Ovarian and uterine functions in female survivors of childhood cancers. Oncologist. 2018;23:214–24. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31:926–37. Dachverband Osteologie e.v. (DVO). Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und Männern, S3 Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftliche Gesellschaften , 2017, AWMF-Register Nr.: 183–001. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol. 2003;157:923–9. Elsheikh M, Bird R, Casadei B, Conway GS, Wass JA. The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner's syndrome. J Clin Endocrinol Metab. 2000;85:614–8. Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors - review of the literature. Pathol Oncol Res. 2019. [Epub ahead of print] Stute P, Bürki R, Geissbühler V. Nicht-hormonelle Therapie von menopausalen Hitzewallungen. SGGG Expertenbrief. . https://www.sggg.ch/fachthemen/expertenbriefe/ Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF), Deutschen Krebsgesellschaft e.V. (DKG) und Deutschen Krebshilfe (DKH). S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms (Version 4.1, 2018) AWMF-Registernummer: 032-045OL. Author information Authors and Affiliations Corresponding author Editor information Editors and Affiliations Rights and permissions Copyright information © 2020 Springer Nature Switzerland AG About this chapter Cite this chapter Ziller, V., Stute, P., von Wolff, M. (2020). Premature Ovarian Insufficiency: Hormone Replacement Therapy and Follow-Up. In: von Wolff, M., Nawroth, F. (eds) Fertility Preservation in Oncological and Non-Oncological Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-47568-0_31 Download citation DOI: https://doi.org/10.1007/978-3-030-47568-0_31 Published: Publisher Name: Springer, Cham Print ISBN: 978-3-030-47567-3 Online ISBN: 978-3-030-47568-0 eBook Packages: MedicineMedicine (R0)